full dosage
Recently Published Documents


TOTAL DOCUMENTS

24
(FIVE YEARS 3)

H-INDEX

4
(FIVE YEARS 1)

Minerals ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 761
Author(s):  
Yunhui Li ◽  
Heather Kaminsky ◽  
Xue Yuki Gong ◽  
Yijia Simon Sun ◽  
Mohammed Ghuzi ◽  
...  

The dewatering of flocculated high density slurry presents a significant challenge to most mining industries. The new technologies to treat high density slurry require a consistent and robust flocculation method in order to enter the market of tailings management. The flocculation of high density slurry, however, due to its complexity, is always a challenge to be undertaken appropriately and to evaluate the dewatering performance correctly. This paper probes the complexity by using a torque-controlled mixing technique to demonstrate the influence of feed properties, polymer type, polymer dosage, and mixing conditions on dewatering performance. The study shows that flocculant should be dosed at the optimal range to achieve the highest dewatering performance. A full dosage responsive curve including under dosage, optimal dosage, and overdosage is critical to evaluate the dewatering performance of high density slurries and flocculants. The mixing conditions such as mixing speed, mixing time, and geometry of the mixing impeller affect the flocculation efficacy. It was found that the dewatering performance of high density slurry is sensitive to solids content, water chemistry, and clay activity. High sodicity and high clay activity in the high density slurry decreases the dewatering performance. Therefore, it is critical to evaluate flocculants across multiple feeds and dosages with replication in order to select optimal dewatering performance. Using multiple key performance indicators (KPIs) to build technical and economic criteria is also critical for polymer evaluation.


Author(s):  
William Gilberto Balbinot ◽  
André Luis Gordechuk ◽  
Géssica Rogaleski Eutrópio ◽  
Cibele Medeiros ◽  
Glória Regina Botelho

Aims: This work aimed to evaluate the effectiveness of A. brasilense inoculants to the development of wheat at the southern part of Brazil. Study Design: The experimental design was randomized block with twelve treatments, containing two liquid inoculants with the A. brasilense strains Ab-V5 and Ab-V6, with or without nitrogen fertilization and five replicates. The plot area was 4m per 6m and thirty-two rows. The seeds inoculation was performed according to the manufacturer's recommendation, and manual sowing. The top-dressing N fertilization was Urea (Super N- 45%N) at 20 days after emergence (DAE), at 120 kg ha-1 (full dosage) or 60 kg ha-1 (half dosage). Place and Duration of Study: The experiment was performed in a farm in Curitibanos county in Santa Catarina state, Brazil. The experiment was carried out on July to November 2016. Methodology: At 45 DAE, it was performed flag leaves N content Tedesco, et al. [1]. At 115 DAE, it was performed dry shoot weight, plant height, ear sizes, grain N contents and grain yield. The results were submitted to variance analysis (ANOVA) and media compared by Scott-Knot's test at 5% of significance. Results: There was no statistical difference for shoot dry weight, plant height, ear size and yield. The N leaf content was greater with Ab-V5 inoculation and half N dosage (HC5 - 109% higher than the control). The N grain content was greater with the two strains (inoculant B) without, half and full N dosage (WC56 - 51%, HCB56 - 76% and CB56 - 65%, respectively). Conclusion: A. brasilense strains had the ability to increase wheat N accumulation with lower N fertilizing, suggesting their potential as growth inducers, emphasizing the importance of further studies to confirm and understand the mechanisms involved.


2019 ◽  
Vol 8 (6) ◽  
pp. 877 ◽  
Author(s):  
Concetta Conticello ◽  
Alessandra Romano ◽  
Vittorio Del Fabro ◽  
Enrica Antonia Martino ◽  
Valeria Calafiore ◽  
...  

Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we report real life results of KRd given to 130 RRMM patients from 12 Sicilian Centers. Results: Median age was 62 years; patients had received a median of two previous lines of treatment (range 1–10) and 52% were refractory to previous treatment. Median number of KRd cycles was 12 (2–29), with a mean duration of treatment of 12 months; 21 patients had received at least 18 cycles. Overall response rate was 61%, including 18% complete response. Median PFS was 22.9 months, median OS was not reached. Creatinine clearance >30 mL/min, quality of the best achieved response and standard Fluorescence In Situ Hybridization (FISH) risk were independent predictors of favorable outcome. Patients who received the full-dosage of carfilzomib in the first two cycles had a better outcome. Conclusions: KRd was effective and well tolerated and in a considerable proportion of patients, therapy continued beyond the 18th cycle. The finding of a better outcome in patients with the higher cumulative dose of carfilzomib in the first two cycle encourages to maintain the maximum tolerated dose.


2017 ◽  
Vol 38 (SI 2 - 6th Conf EFPP 2002) ◽  
pp. 652-655
Author(s):  
I. Gaurilčikienė

The trials were carried out over the period 1999–2000 with a view to testing the efficacy of reduced doses of triazole fungicides on winter wheat cv. Zentos. Septoria diseases (Septoria spp.) occurred on winter wheat annually. Full and reduced dosages of fungicides were highly effective against Septoria leaf blotch at an early milk stage, especially on flag leaf. Later the efficacy of reduced dosages of the fungicides was lower, than that of full doses. Due to full dosage of fungicides we obtained a sufficient yield increase annually. The yield increase through the use of 3⁄4 reduced doses was lower. But yield increase through reduced dosage to 1⁄2 was low and insufficient.


Author(s):  
Md Shafiqul Islam ◽  
Monjur Hasan

2.7 billion people worldwide rely on onsite sanitation and it is a big problem in developing countries. Faecal sludge is a good source of micro/macronutrients of plant besides its richness in organic matter. Two consecutive field experiments was conducted in BRAC Agricultural Research and Development Centre, Gazipur during Rabi 2015-16 and rabi 2016-17 aimed to determine the effect of faecal sludge on crop production and how much dosage need for maximum yield. Cabbage was the test crop. It was observed that harvesting time was significantly shortened and 25.51% curd weight and 26.55% yield was increase with addition of faecal and chemical fertilizer. No significant differences were found on the dosage of faecal on head formation and head diameter. In the addition of full dosage of faecal with chemical fertilizer, 41.04% and 8.61% curd weight increase than only faecal and chemical fertilizer. Application of full dosage of faecal with full dosages of chemical increases yield 7.28%, 10.66%, 6.88% and 38.75 % than application of half faecal, three-fourth faecal, only chemical fertilizer and only faecal. So addition of full dosage of faecal with chemical fertilizer gives the highest yield on crop. In Bangladesh, faecal might be recycled into agricultural soils as a supplement to commercial fertilizer and thereby enrich the general fertility of the soils and increase crop production.Int. J. Agril. Res. Innov. & Tech. 7 (1): 43-45, June, 2017


2016 ◽  
Vol 69 (6) ◽  
Author(s):  
Stephanie Carlin ◽  
Jennifer Pickering ◽  
Sam Schulman

<p><strong>ABSTRACT</strong></p><p><strong>Background:</strong> The ARISTOTLE study investigated apixaban, at a dose of 5 mg PO bid, for the prevention of stroke in patients with atrial fibrillation; however, it has been noted anecdotally that many patients are receiving 2.5 mg PO bid, despite being eligible for the full dosage. A recent study examining the use of dabigatran and rivaroxaban found that many patients were receiving these medications inappropriately; however, a literature search conducted in April 2016 showed that apixaban had not been formally studied in this context.</p><p><strong>Objective:</strong> To evaluate the appropriateness of apixaban dosing for stroke prevention in patients with atrial fibrillation, relative to the dose used in the ARISTOTLE study and recommendations in the product monograph.</p><p><strong>Methods:</strong> This retrospective chart review was conducted at a 300-bed Canadian teaching hospital. All inpatients with atrial fibrillation for whom apixaban was prescribed for stroke prevention in March 2015 were considered for inclusion. The appropriateness of apixaban dosing was determined in relation to the ARISTOTLE methodology and product monograph recommendations (i.e., 5 mg PO bid, with a lower dosage of 2.5 mg PO bid if warranted on the basis of age, weight, or serum creatinine level).</p><p><strong>Results:</strong> A total of 47 patients were included, of whom 25 (53%) were receiving apixaban inconsistent with the ARISTOTLE study and the product monograph. Limitations of the current study included small sample size, single-centre setting, and retrospective design, which precluded determination of each prescriber’s rationale for dosage choice.</p><p><strong>Conclusions:</strong> Pharmacists and physicians should be vigilant in ensuring that patients with atrial fibrillation are receiving the appropriate dosage of apixaban to optimize the risk–benefit ratio of this therapy.</p><p><strong>RÉSUMÉ</strong></p><p><strong>Contexte :</strong> L’étude ARISTOTLE portait sur l’utilisation de l’apixaban pour la prévention des accidents vasculaires cérébraux (AVC) chez les patients souffrant de fibrillation auriculaire à raison d’une dose de 5 mg par voie orale deux fois par jour. Or, des observations empiriques montrent que bon nombre de patients reçoivent une dose de 2,5 mg par voie orale deux fois par jour, même s’ils se qualifient pour la pleine dose. Une étude récente portant sur l’utilisation du dabigatran et du rivaroxaban a relevé que bon nombre de patients recevaient ces médicaments de façon inappropriée. Or, une recherche bibliographique effectuée en avril 2016 a révélé que l’apixaban n’a pas été officiellement étudié dans ce contexte.</p><p><strong>Objectif :</strong> Évaluer la pertinence du schéma posologique d’apixaban pour la prévention des AVC chez les patients souffrant de fibrillation auriculaire comparativement à la dose utilisée dans l’étude ARISTOTLE et aux recommandations contenues dans la monographie de produit.</p><p><strong>Méthodes :</strong> La présente analyse rétrospective de dossiers médicaux a été menée dans un seul centre hospitalier universitaire canadien de 300 lits. Tous les patients hospitalisés atteints de fibrillation auriculaire pour qui l’on a prescrit de l’apixaban afin de prévenir l’AVC en mars 2015 ont été pris en considération. La pertinence du schéma posologique d’apixaban était établie par rapport à la méthodologie de l’étude ARISTOTLE et aux recommandations de la monographie de produit (c’est-à-dire une dose de 5 mg par voie orale deux fois par jour et une dose réduite de 2,5 mg par voie orale deux fois par jour si l’âge, le poids et le taux de créatinine sérique la justifiaient).</p><p><strong>Résultats :</strong> Au total, 47 patients ont été admis. L’administration de l’apixaban n’était pas conforme à l’étude ARISTOTLE et à la monographie de produit chez 25 (53 %) d’entre eux. Parmi les limites de la présente étude, on comptait la petite taille de l’échantillon, son déroulement dans un seul centre et l’utilisation d’un plan d’étude rétrospectif qui empêchait de<br />comprendre les raisons motivant le choix de posologie de chaque prescripteur.</p><p><strong>Conclusions :</strong> Les pharmaciens et les médecins doivent être vigilants et s’assurer que les patients atteints de fibrillation auriculaire reçoivent la posologie appropriée d’apixaban permettant d’optimiser le rapport bénéfice-risque de ce traitement.</p>


2016 ◽  
Vol 81 (1) ◽  
Author(s):  
Laksmita Prima SANTI ◽  
Didiek Hadjar GOENADI

AbstractOil palm plantation at Central Kalimantan hasbeen expanded to those areas with sandy-textured soil.This type of soil has limiting factors for plant growth, i.e.unstable soil aggregation and weak organic complexbond that restrain root development and yield. However,efforts to solve this problem are very limited. Theresearch aimed to develop technology to improve theinteractions for promoting a stable soil aggregate ofsandy-textured soil. The use of exopolysaccharideproducing bacteria as a soil bio-ameliorant to mediatesandy soil micro aggregate formation by bio-augmenta-tion technique has become an accepted practice. A highlypotential endophytic bacterium for exopolysaccharidesproduction was isolated from a sandy soil located atKotawaringin Barat-Central Kalimantan. The bacteriumwas identified as Burkholderia cenocepacia KTG strain.The field experiment has been organized according to themethod of randomized complete blocks design with seventreatments of fertilizer in combination with bio-ameliorant and replicated three times. Fertilizer and bio-ameliorant application has been done in November 2009- November 2011. Field trial was evaluated based on theproduction of mature oil palm during January 2010-December 2011 periods. The data obtained indicate thatapplication of bio-ameliorant combined with reduceddosage of N-P-K 16-4-25 was not significantly differentto that of full dosage of N-P-K 16-4-25 treatment.AbstrakPengembangan perkebunan kelapa sawit diKalimantan Tengah telah masuk ke wilayah dengan tanahtekstur berpasir. Jenis tanah ini memiliki faktor pembatasbagi pertumbuhan tanaman seperti ketidakstabilan agregattanah serta ikatan organik kompleks yang lemah,sehingga perkembangan akar tanaman akan mengalamihambatan dan pada akhirnya produktivitas menjadi suboptimal. Bagaimanapun juga, upaya untuk memecahkanmasalah tersebut masih sangat terbatas. Penelitian inibertujuan mengembangkan teknologi untuk meningkat-kan kemantapan agregat tanah tekstur berpasir. Pem-bentukan mikro agregasi tanah dengan memanfaatkanbakteri penghasil eksopolisakarida sebagai pembenahhayati melalui teknik bioaugmentasi merupakan teknologiyang dapat diterapkan secara praktis di lapang. Bakteriendofitik penghasil eksopolisakarida potensial telah ber-hasil diisolasi dari tanah tekstur berpasir, di daerahKotawaringin Barat, Kalimantan Tengah. Bakteri ini di-identifikasi sebagai Burkholderia cenocepacia strainKTG. Tujuh perlakuan yang diuji merupakan kombinasipupuk dan pembenah tanah hayati dengan tiga ulangan.Aplikasi pupuk dan pembenah tanah hayati ini dilakukanselama periode Nopember 2009 - Nopember 2011.Evaluasi dilakukan atas dasar tingkat produktivitaskelapa sawit yang sudah berproduksi selama 16 tahunselama periode Januari 2010 - Desember 2011. Data yangdiperoleh menunjukkan bahwa dosis pembenah tanahyang diuji yang dikom-binasikan dengan penurunan dosispupuk N-P-K 16-4-25 tidak berbeda nyata denganperlakuan penggunaan dosis penuh pupuk N-P-K 16-4-25.


2016 ◽  
Vol 81 (1) ◽  
Author(s):  
Laksmita Prima SANTI ◽  
Didiek Hadjar GOENADI

AbstractOil palm plantation at Central Kalimantan hasbeen expanded to those areas with sandy-textured soil.This type of soil has limiting factors for plant growth, i.e.unstable soil aggregation and weak organic complexbond that restrain root development and yield. However,efforts to solve this problem are very limited. Theresearch aimed to develop technology to improve theinteractions for promoting a stable soil aggregate ofsandy-textured soil. The use of exopolysaccharideproducing bacteria as a soil bio-ameliorant to mediatesandy soil micro aggregate formation by bio-augmenta-tion technique has become an accepted practice. A highlypotential endophytic bacterium for exopolysaccharidesproduction was isolated from a sandy soil located atKotawaringin Barat-Central Kalimantan. The bacteriumwas identified as Burkholderia cenocepacia KTG strain.The field experiment has been organized according to themethod of randomized complete blocks design with seventreatments of fertilizer in combination with bio-ameliorant and replicated three times. Fertilizer and bio-ameliorant application has been done in November 2009- November 2011. Field trial was evaluated based on theproduction of mature oil palm during January 2010-December 2011 periods. The data obtained indicate thatapplication of bio-ameliorant combined with reduceddosage of N-P-K 16-4-25 was not significantly differentto that of full dosage of N-P-K 16-4-25 treatment.AbstrakPengembangan perkebunan kelapa sawit diKalimantan Tengah telah masuk ke wilayah dengan tanahtekstur berpasir. Jenis tanah ini memiliki faktor pembatasbagi pertumbuhan tanaman seperti ketidakstabilan agregattanah serta ikatan organik kompleks yang lemah,sehingga perkembangan akar tanaman akan mengalamihambatan dan pada akhirnya produktivitas menjadi suboptimal. Bagaimanapun juga, upaya untuk memecahkanmasalah tersebut masih sangat terbatas. Penelitian inibertujuan mengembangkan teknologi untuk meningkat-kan kemantapan agregat tanah tekstur berpasir. Pem-bentukan mikro agregasi tanah dengan memanfaatkanbakteri penghasil eksopolisakarida sebagai pembenahhayati melalui teknik bioaugmentasi merupakan teknologiyang dapat diterapkan secara praktis di lapang. Bakteriendofitik penghasil eksopolisakarida potensial telah ber-hasil diisolasi dari tanah tekstur berpasir, di daerahKotawaringin Barat, Kalimantan Tengah. Bakteri ini di-identifikasi sebagai Burkholderia cenocepacia strainKTG. Tujuh perlakuan yang diuji merupakan kombinasipupuk dan pembenah tanah hayati dengan tiga ulangan.Aplikasi pupuk dan pembenah tanah hayati ini dilakukanselama periode Nopember 2009 - Nopember 2011.Evaluasi dilakukan atas dasar tingkat produktivitaskelapa sawit yang sudah berproduksi selama 16 tahunselama periode Januari 2010 - Desember 2011. Data yangdiperoleh menunjukkan bahwa dosis pembenah tanahyang diuji yang dikom-binasikan dengan penurunan dosispupuk N-P-K 16-4-25 tidak berbeda nyata denganperlakuan penggunaan dosis penuh pupuk N-P-K 16-4-25.


2016 ◽  
Vol 33 (S1) ◽  
pp. S612-S612
Author(s):  
F.X. Fluvia ◽  
R. Pastor

It is well known that when we have a schizophrenic patient who do not respond to two batches of neuroleptics at full dosage for more than six month, it may be wise to try with clozpine which is believed to be one of the best neuroleptics we have but with two main handicaps: it can produce leucopenia which can be fatal and epileptic seizures as well. We do think that in many cases, clozapine has been used too soon in the treatment of the schizophrenic patient, before we can really talk of a resistant patient. To prove that we have changed the clozapine treatment of four chronically ill schizophrenic patients admitted to a home for the chronically mentally ill. Two patients were changed from clozapine 400 mg/day to paliperidone 15 mg/day along two months time. They both improved in mental clarity and ability of thinking. Another patient were changed from 600 mg/day to 27 mg/day of paliperidone. That patient worsened a little bit mainly with hostility and social avoidance but it was mandatory to change neuroleptic because he had had two seizures and had low levels of platelets and therefore he was at risk of developing leukopenia. The fourth one was taking 300 mg of clozapine and was changed to 12 mg of paliperidone. We got no change in the clinical outcome.DiscussionWe discuss the different explanations for the results we got.Disclosure of interestThe authors have not supplied their declaration of competing interest.


2014 ◽  
Vol 10 (2) ◽  
pp. 80-84
Author(s):  
A Rahim ◽  
M Moniruzzaman ◽  
FI Khan ◽  
MM Rahman

A 55-year-old woman was presented with fever, splenomegaly, generalized lymphadenopathy and weight loss. The patient came from Sreepur, an endemic region of Kala-azar in Bangladesh. About 2 years back, the patient presented with fever and splenomegaly and on investigation, ICT for Kala-azar was found positive. Thus the patient was diagnosed as a case of visceral Leishmaniasis and was treated with Miltefosin in full dosage form. The condition was improved with the treatment. After about a year of treatment the patient again developed fever and splenomegaly? this time was also generalized lymphadenopathy. Lymph node biopsy showed non-Hodgkin’s lymphoma and bone marrow study showed the presence of LD-bodies. FNAC from cervical and epitrochlear lymph nodes showed the presence of LD bodies without the presence of any malignant cells, so she was diagnosed as a case of treatment failure of visceral Leishmaniasis with lymphatic involvement. DOI: http://dx.doi.org/10.3329/jsf.v10i2.17961 J Sci Found, 2012;10(2):80-84


Sign in / Sign up

Export Citation Format

Share Document